PURPOSE: To demonstrate the clinical translation of optical molecular imaging (OMI) for the localization of focal hepatic lesions during percutaneous hepatic interventions. MATERIALS AND METHODS: Institutional review board approval was obtained for this prospective, single-center, HIPAA-compliant trial. Patients who were suspected of having hepatocellular carcinoma or liver metastases from colorectal cancer and were scheduled for percutaneous liver biopsy or thermal ablation were eligible for this study. Patients (n = 5) received 0.5 mg per kilogram of body weight of indocyanine green (ICG) intravenously 24 hours prior to their scheduled procedure in this study. Intraprocedurally, a handheld device composed of an endoscope that fits coaxially through a standard 17-gauge introducer needle was advanced into the liver, and real-time measurements of ICG fluorescence were obtained. A point-of-care fluorescence imaging system was used to image ICG fluorescence in biopsy samples. Target-to-background ratios (TBRs) were calculated by dividing the mean fluorescence intensity in the lesion by the mean fluorescence intensity in the adjacent liver parenchyma. The reference standard for determination of proper needle positioning in patients undergoing biopsy was final pathologic analysis of biopsy specimens or follow-up imaging. RESULTS: Intraprocedural OMI was successfully performed in six lesions (two lesions in patient 3) in five patients. The median size of the targeted lesions was 16 mm (range, 10-21 mm). Four of five biopsies (80%) yielded an accurate pathologic diagnosis, and one biopsy specimen showed benign liver parenchyma; both ablated lesions showed no residual disease 1 month after the procedure. The median overall added procedure time to perform OMI was 2 minutes. ICG was found to localize with TBRs greater than 2.0 (median, 7.9; range, 2.4-13.4) in all target lesions. No trial-related adverse events were reported. CONCLUSION: The clinical translation of OMI to percutaneous hepatic interventions was demonstrated.
PURPOSE: To demonstrate the clinical translation of optical molecular imaging (OMI) for the localization of focal hepatic lesions during percutaneous hepatic interventions. MATERIALS AND METHODS: Institutional review board approval was obtained for this prospective, single-center, HIPAA-compliant trial. Patients who were suspected of having hepatocellular carcinoma or liver metastases from colorectal cancer and were scheduled for percutaneous liver biopsy or thermal ablation were eligible for this study. Patients (n = 5) received 0.5 mg per kilogram of body weight of indocyanine green (ICG) intravenously 24 hours prior to their scheduled procedure in this study. Intraprocedurally, a handheld device composed of an endoscope that fits coaxially through a standard 17-gauge introducer needle was advanced into the liver, and real-time measurements of ICG fluorescence were obtained. A point-of-care fluorescence imaging system was used to image ICG fluorescence in biopsy samples. Target-to-background ratios (TBRs) were calculated by dividing the mean fluorescence intensity in the lesion by the mean fluorescence intensity in the adjacent liver parenchyma. The reference standard for determination of proper needle positioning in patients undergoing biopsy was final pathologic analysis of biopsy specimens or follow-up imaging. RESULTS: Intraprocedural OMI was successfully performed in six lesions (two lesions in patient 3) in five patients. The median size of the targeted lesions was 16 mm (range, 10-21 mm). Four of five biopsies (80%) yielded an accurate pathologic diagnosis, and one biopsy specimen showed benign liver parenchyma; both ablated lesions showed no residual disease 1 month after the procedure. The median overall added procedure time to perform OMI was 2 minutes. ICG was found to localize with TBRs greater than 2.0 (median, 7.9; range, 2.4-13.4) in all target lesions. No trial-related adverse events were reported. CONCLUSION: The clinical translation of OMI to percutaneous hepatic interventions was demonstrated.
Authors: Boudewijn E Schaafsma; J Sven D Mieog; Merlijn Hutteman; Joost R van der Vorst; Peter J K Kuppen; Clemens W G M Löwik; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer Journal: J Surg Oncol Date: 2011-04-14 Impact factor: 3.454
Authors: Joost R van der Vorst; Boudewijn E Schaafsma; Merlijn Hutteman; Floris P R Verbeek; Gerrit-Jan Liefers; Henk H Hartgrink; Vincent T H B M Smit; Clemens W G M Löwik; Cornelis J H van de Velde; John V Frangioni; Alexander L Vahrmeijer Journal: Cancer Date: 2013-06-21 Impact factor: 6.860
Authors: Martin Goetz; Alex Ziebart; Sebastian Foersch; Michael Vieth; Maximilian J Waldner; Peter Delaney; Peter R Galle; Markus F Neurath; Ralf Kiesslich Journal: Gastroenterology Date: 2009-10-21 Impact factor: 22.682
Authors: Alda L Tam; Howard J Lim; Ignacio I Wistuba; Anobel Tamrazi; Michael D Kuo; Etay Ziv; Stephen Wong; Albert J Shih; Robert J Webster; Gregory S Fischer; Sunitha Nagrath; Suzanne E Davis; Sarah B White; Kamran Ahrar Journal: J Vasc Interv Radiol Date: 2015-11-25 Impact factor: 3.464
Authors: Shadi A Esfahani; Pedram Heidari; Melanie H Kucherlapati; Jorge M Ferrer; Raju S Kucherlapati; Umar Mahmood Journal: Am J Nucl Med Mol Imaging Date: 2019-10-15
Authors: Xuefeng Kan; Feng Zhang; Guanhui Zhou; Hongxiu Ji; Wayne Monsky; Christopher Ingraham; Chuansheng Zheng; Xiaoming Yang Journal: Proc Natl Acad Sci U S A Date: 2021-10-12 Impact factor: 11.205
Authors: Katherine V Ferry-Galow; Vivekananda Datta; Hala R Makhlouf; John Wright; Bradford J Wood; Elliot Levy; Etta D Pisano; Alda L Tam; Susanna I Lee; Umar Mahmood; Lawrence V Rubinstein; James H Doroshow; Alice P Chen Journal: J Oncol Pract Date: 2018-10-04 Impact factor: 3.840
Authors: Melodi Javid Whitley; Diana M Cardona; Alexander L Lazarides; Ivan Spasojevic; Jorge M Ferrer; Joan Cahill; Chang-Lung Lee; Matija Snuderl; Dan G Blazer; E Shelley Hwang; Rachel A Greenup; Paul J Mosca; Jeffrey K Mito; Kyle C Cuneo; Nicole A Larrier; Erin K O'Reilly; Richard F Riedel; William C Eward; David B Strasfeld; Dai Fukumura; Rakesh K Jain; W David Lee; Linda G Griffith; Moungi G Bawendi; David G Kirsch; Brian E Brigman Journal: Sci Transl Med Date: 2016-01-06 Impact factor: 17.956
Authors: Chrysafis Andreou; Volker Neuschmelting; Darjus-Felix Tschaharganeh; Chun-Hao Huang; Anton Oseledchyk; Pasquale Iacono; Hazem Karabeber; Rivka R Colen; Lorenzo Mannelli; Scott W Lowe; Moritz F Kircher Journal: ACS Nano Date: 2016-05-10 Impact factor: 15.881
Authors: Quirina M B de Ruiter; Sheng Xu; Ming Li; William F Pritchard; Matthew F Starost; Armando Filie; Andrew S Mikhail; Michal Mauda-Havakuk; Juan A Esparza-Trujillo; Ivane Bakhutashvili; Pedram Heidari; Umar Mahmood; John W Karanian; Bradford J Wood Journal: Cardiovasc Intervent Radiol Date: 2021-05-21 Impact factor: 2.797